Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
TILT Biotherapeutics Ltd.
Modality
gene_therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05271318CT.gov Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tilt-123 (this asset) | TILT Biotherapeutics Ltd. | P1/2 | CC · 47 |
| Carboplatin | Women's Hospital School Of Medicine Zhejiang University | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P3 | BB |
| Tamoxifen | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | P3 | BB |
| Cyclophosphamide | Mayo Clinic | P2 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | BB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | Brigham and Women's Hospital | P3 | BB |
| Atezolizumab | Ronald Buckanovich | P2/3 | BB |
+42 more in the Fallopian Tube Carcinoma cohort
Other indications for Tilt-123
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P1/2 | CCC · 48 |
| Primary Peritoneal Carcinoma | — | P1/2 | CC · 47 |
| Ovarian Cancer | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tilt-123 in Fallopian Tube Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tilt-123-fallopian-tube-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →